Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: H2S has been increasingly found to contribute to different (patho-)physiological processes such as blood pressure regulation and scavenging of reactive oxygen species. A deficiency of H2S-producing enzymes results in hypertension, and administration of H2S donors lowers blood pressure and protects against organ damage in the experimental setting. Thiosulfate, a H2S metabolite, can act as a H2S donor, and is already clinically used for the treatment of calciphylaxis in patients with end-stage renal disease. Treatment of hypertensive rats with thiosulfate results in lower blood pressure and reduces organ damage. SUMMARY: Although human data on H2S and hypertension are scarce, experimental data indicate that elevation of H2S levels using dietary sulfate or exogenous H2S (donors) could be a promising therapeutic strategy in the setting of hypertension.
|
Authors | Harry van Goor, Joost C van den Born, Jan-Luuk Hillebrands, Jaap A Joles |
Journal | Current opinion in nephrology and hypertension
(Curr Opin Nephrol Hypertens)
Vol. 25
Issue 2
Pg. 107-13
(Mar 2016)
ISSN: 1473-6543 [Electronic] England |
PMID | 26808704
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antihypertensive Agents
- Thiosulfates
- Hydrogen Sulfide
|
Topics |
- Animals
- Antihypertensive Agents
(therapeutic use)
- Blood Pressure
(drug effects)
- Humans
- Hydrogen Sulfide
(metabolism, pharmacology, therapeutic use)
- Hypertension
(drug therapy, metabolism)
- Thiosulfates
(therapeutic use)
|